title: [Efficiency of high-dose FEC chemotherapy for the mobilization of hematopoietic stem cells into peripheral blood].
abstract: The best regimen for mobilizing hematopoietic stem cells (HSC) into peripheral blood is not yet defined. The efficiency of FEC chemotherapy in the treatment of breast cancer is well established and the effects of FEC on HSC mobilization have been characterized. We tested the feasibility and the toxicity of a high-dose FEC regimen which may improve the mobilizing capacity of conventional FEC. Twenty patients with poor prognosis breast cancer received high-dose FEC and filgrastim 5 micrograms/kg. Three leukaphereses were performed on each patient for 3 consecutive days. Total numbers of CFU-GM and CD34+ cells were assessed, and a retrospective analysis was made. The numbers of CFU-GM/kg and CD34+ cells/kg collected (mean +/- standard error) were respectively 12.2 x 10(5) (+/- 2.4) and 14.6 x 10(6) (+/- 2.5). Extra-hematologic toxicity was negligible. Hematologic recovery after CTCb high-dose chemotherapy and HSC infusion was rapid. High-dose FEC is efficient for collecting HSC in peripheral blood. Extra-hematologic toxicity is weak and hematologic recovery after autograft is normal. Increased dosage of epirubicin and cyclophosphamide could allow a single leukapheresis collection of sufficient HSC from peripheral blood.
authors.affiliation: Service d'oncologie médicale, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Bruxelles, Belgique.
authors.forename: L
authors.initials: L
authors.lastname: D'Hondt
authors.forename: M
authors.initials: M
authors.lastname: André
authors.forename: J L
authors.initials: JL
authors.lastname: Canon
authors.forename: T
authors.initials: T
authors.lastname: Guillaume
authors.forename: C
authors.initials: C
authors.lastname: Doyen
authors.forename: A M
authors.initials: AM
authors.lastname: Feyens
authors.forename: B
authors.initials: B
authors.lastname: Chatelain
authors.forename: A
authors.initials: A
authors.lastname: Dromelet
authors.forename: Y
authors.initials: Y
authors.lastname: Humblet
authors.forename: J
authors.initials: J
authors.lastname: Longueville
authors.forename: M
authors.initials: M
authors.lastname: Symann
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001772:Blood Cell Count / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D000069585:Filgrastim; D005472:Fluorouracil / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007937:Leukapheresis; D008875:Middle Aged; D009367:Neoplasm Staging; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D003520:Cyclophosphamide; D000069585:Filgrastim; D005472:Fluorouracil